|
Orthologous residues
|
|
NFkB‑p65 (human): S276‑p, NFkB‑p65 (mouse): S276‑p, NFkB‑p65 (rat): S276‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
cervical cancer, cervical adenocarcinoma, lung cancer
|
|
Relevant cell lines - cell types - tissues:
A549 (pulmonary), HeLa S3 (cervical), MEF (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TNF
|
|
|
|
increase
|
|
|
DMSO
|
TNF
|
|
|
inhibit treatment-induced increase
|
|
|
NAC
|
TNF
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
transcription, altered
|
